Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816

E. Felip,C. Wang,T-E. Ciuleanu,G. Saylors,F. Tanaka,K-N. Chen, H. Ito,N. Girard,S. Lu,M. Provencio Pulla,T. Mitsudomi,M. Awad,P. M. Forde,R. Lawrance,F. Taylor, G. Worthy,S. I. Blum,L. Vo,J. L. Cai,J. Spicer

ANNALS OF ONCOLOGY（2022）

Cited 0|Views3
No score
Abstract
CheckMate 816 (NCT02998528), a phase 3 study, met its primary endpoints of statistically significant and clinically meaningful improvements in event-free survival and pathological complete response with neoadjuvant NIVO + chemo vs chemo for resectable NSCLC. We present HRQoL results from the neoadjuvant treatment period.
More
Translated text
Key words
lung cancer,nivolumab,chemotherapy,neoadjuvant treatment,platinum-doublet,non-small,health-related
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined